Multifocality Appears to Increase Risk of Recurrence in Papillary Thyroid Carcinoma
The risk of recurrence varied by patient age, tumor size, and number of foci.
Thyroid Cancer
Vandetanib and Cabozantinib Deemed Effective in Real-World Study of Medullary Thyroid Cancer
The overall survival rate at 1 year was 86% with vandetanib and 70% with cabozantinib.
Local Resection Is ‘Sufficient’ for Parathyroid Carcinoma
Patients with parathyroid carcinoma after localized resection for a presumed benign indication should undergo close monitoring for recurrence rather than radical surgery.
Mutational Risk Not Associated With Distant Metastasis in Medullary Thyroid Cancer
Researchers identified risk factors for distant metastasis in sporadic and hereditary medullary thyroid cancer.
Cabozantinib Gets Breakthrough Tx Status for Differentiated Thyroid Cancer
The designation is supported by data from the randomized, double-blind, placebo-controlled phase 3 COSMIC-311 study.
Exposure to Light at Night May Increase Risk for Thyroid Cancer
Investigators tested the hypothesis that greater exposure to light at night (LAN) is associated with an increased risk for thyroid cancer by studying artificial outdoor LAN measured by satellite imagery in relation to thyroid cancer.
Artificial Light at Night Tied to Thyroid Cancer Risk
Positive association mainly driven by incidence of papillary thyroid cancer.
Thyroid Carcinoma Treatment Regimens
Find information about available non-chemotherapy treatments for thyroid carcinoma, including total thyroidectomy, radiodine treatment, and ablation.
Gavreto Gets Accelerated Approval for RET-Altered Thyroid Cancers
The approval was based on data from the phase 1/2 ARROW trial which evaluated the efficacy and safety of Gavreto in patients with RET-mutant MTC.
RET Inhibitor Demonstrates Efficacy in RET-Altered Thyroid Cancer
Treatment of RET-altered thyroid cancer with selpercatinib, a RET inhibitor, resulted in durable efficacy with a tolerable safety profile in a phase 1/2 trial.
- Loading...
Loading...
Next post in Head and Neck Cancer
Loading... 
Loading...